Acute reversible ataxo-myoclonic encephalopathy with flecainide therapy.
A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide. The clinical picture was characterized by visual hallucinations, agitation, anxiety, but no disorientation, and a severe cerebello-myoclonic syndrome with total inability to stand up and walk, which was fully reversible on discontinuing the medication.
Ghika
J
J
Service de Neurologie, CHUV, Lausanne, Switzerland.
Goy
J J
JJ
Naegeli
C
C
Regli
F
F
D000368:Aged; D002524:Cerebellar Ataxia / Q000139:chemically induced*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005424:Flecainide / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008297:Male; D009207:Myoclonus / Q000139:chemically induced*; D009460:Neurologic Examination / Q000187:drug effects; D012307:Risk Factors; D013617:Tachycardia, Supraventricular / Q000188:drug therapy*; D014927:Wolff-Parkinson-White Syndrome / Q000188:drug therapy*
D005424:Flecainide